Clinical trials: Cancer of Oropharynx
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Head and Neck Cancer, Melanoma
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient…
- Conditions
- Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma
- Trial name
- NCT05061940
- Testing
- Tumor Profiling
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Repertoire Immune Medicines
Stomatitis
EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation
This is a Phase 2, randomized, double-blind, placebo-controlled, 2-stage trial in subjects with squamous cell cancers of the mouth, oropharynx, hypopharynx and nasopharynx planned to receive standard fractionated IMRT-delivered…
- Trial name
- NCT03200340
- Testing
- EC-18
- Where
- 20 sites in United States
- Volunteers
- 105 people
- Sponsor
- Enzychem Lifesciences Corporation
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Head and Neck Cancer
Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Inserting the gene for p53 into a person's tumor may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
- Trial name
- NCT00003257
- Testing
- Ad5CMV-p53 gene
- Where
- 10 sites in United States
- Volunteers
- 39 people
- Sponsor
- Aventis Pharmaceuticals
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).
- Trial name
- FORTIFI-HN01 (NCT06788990)
- Testing
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
- Where
- 231 sites in United States, Argentina and 26 more
- Volunteers
- 650 people
- Sponsor
- Bicara Therapeutics
Head and Neck Cancer
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell…
- Trial name
- NCT05386550
- Testing
- Xevinapant, IMRT
- Where
- 206 sites in United States, Argentina and 24 more
- Volunteers
- 166 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.
- Trial name
- NCT03669718
- Testing
- ISA101b, Cemiplimab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 194 people
- Sponsor
- ISA Pharmaceuticals
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Solid Tumor, Microsatellite Stable Colorectal Cancer
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
- Conditions
- Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- RAPTOR (NCT04301011)
- Testing
- TBio-6517, Pembrolizumab
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- Turnstone Biologics, Corp.
Stomatitis, Radiation Effects
Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx
The purpose of this study is to compare the effectiveness and safety of benzydamine hydrochloride 0.15% oral rinse to a vehicle oral rinse in the treatment of radiation-induced oral mucositis, and to compare the care normally…
- Trial name
- NCT00051441
- Testing
- Benzydamine Hydrochloride 0.15% Oral Rinse
- Volunteers
- 605 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Oropharyngeal Squamous Cell Carcinoma (SCC)
Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
A clinical study of an immunotherapy in patients with head or neck cancers associated with the HPV16 virus
- Trial name
- NCT06589609
- Testing
- FluBHPVE6E7
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- BlueSky Immunotherapies GmbH
Head and Neck Neoplasms
Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
- Trial name
- NCT00094081
- Testing
- tirapazamine (SR259075), cisplatin, Radiation Therapy
- Where
- 10 sites in United States
- Volunteers
- 861 people
- Sponsor
- Sanofi
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Head and Neck Cancer
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or…
- Trial name
- NCT00003327
- Testing
- paclitaxel
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Theradex
Mouth Diseases, Mouth Ulcers
Safety and Efficacy of RK0202 in Oral Mucositis
The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis in subjects receiving radiation therapy for head and neck cancer.
- Conditions
- Mouth Diseases, Mouth Ulcers, Oral Mucositis, Head and Neck Cancer
- Trial name
- NCT00230191
- Testing
- RK-0202
- Where
- 9 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- RxKinetix
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma, Unknown Primary
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
This is a single-arm, single site, multi-surgeon prospective feasibility study for transoral robot assisted surgery (TORS) with the Versius Surgical System.
- Trial name
- NCT06112535
- Testing
- Versius Surgical System
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- CMR Surgical Ltd
Head and Neck Cancer
Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003328
- Testing
- porfiromycin, radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Advanced Head and Neck Squamous Cell Carcinoma
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab.
- Trial name
- NCT03254927
- Testing
- CDX-3379 and cetuximab
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Celldex Therapeutics